Interim Report January – September 2019

BioArctic: Strong continued progress year to date Summary of key events for the third quarter 2019 BioArctic and Eisai presented new data regarding BAN2401 at ...

Interim Report January – March 2019

BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program started 

BioArctic publishes the Annual Report for 2018

Stockholm, Sweden, April 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2018 fiscal year has been ...

Full Year Report January – December 2018

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio

Proud partner of: